Vincent Meliso
Foot Surgery · Brooklyn, NYNPI 1578535209
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,368 of the $5,935 with a category attached, or 73.6%. 20 manufacturers reported payments, led by Nevro Corp. at 38.7% of the total. Reporting peaked in 2022 at $2,425 and has fallen 90.7% since, to $225 in 2025. Among foot surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $42.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$2K
- Medimetriks Pharmaceuticals, Inc.$719
- Amgen$550
- Smith+Nephew$440
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$301
- Integra Lifesciences Corporation$260
- plus $1K from 14 others
What the payments were for
- Consulting fees$70012%
- Travel & lodging$86515%
- Food & beverage$4,36874%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 21 | $2,295 |
| Medimetriks Pharmaceuticals, Inc. | 3 | $719 |
| Amgen | 36 | $550 |
| Smith+Nephew | 19 | $440 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 15 | $301 |
| Integra Lifesciences Corporation | 3 | $260 |
| Kerecis Limited | 3 | $229 |
| Treace Medical Concepts, Inc. | 3 | $219 |
| Paratek Pharmaceuticals, Inc. | 9 | $174 |
| Pfizer | 8 | $149 |
| Royal Biologics, Inc. | 1 | $145 |
| Stryker | 1 | $117 |
| Sebela Pharmaceuticals Inc. | 5 | $111 |
| Merck | 4 | $56 |
| Novartis | 2 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Melinta Therapeutics, LLC | 1 | $23 |
| Galderma Laboratories, L.p. | 1 | $22 |
| Organon | 1 | $21 |
| Advanced Oxygen Therapy Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza$1,569
- Neo-Synalar$700
- Kerecis Omega3 Marigen$568
- INTEGRA$369
- Synalar$350
- Genadur$350
- Tovet (emollient formulation)$350
- Lapiplasty System$168
- Fibrinet$145
- Kerecis Omega3 SurgiClose$142
- Omnia$129
- INTEGRA DERMAL REGENERATION TEMPLATE$123
- PRIMATRIX$123
- SALTO TALARIS TOTAL ANKLE PROSTHESIS$121
- CADENCE ANKLE REPLACEMENT SYSTEM$121
- HALLU-LOCK$121
- PANTA NAIL$121
- TOTAL FOOT SYSTEM$121
- Santyl$119
- REGRANEX$119
How this compares
$5,935 in reported general payments places this provider in the 90th percentile of 294 foot surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JubliaEfinaconazole | 49 | $44,775 |
| SantylCollagenase Clostridium Hist. | 23 | $17,567 |
| Tavaborole | 13 | $11,597 |
| CiclopiroxCiclopirox Olamine | 250 | $6,647 |
| Diclofenac Potassium | 16 | $4,559 |
| Doxepin Hcl | 17 | $4,427 |
| Diclofenac Sodium | 92 | $1,840 |
| Celecoxib | 38 | $1,293 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 35 | $771 |
| Pregabalin | 56 | $683 |
| Gabapentin | 136 | $631 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 58 | $597 |
| Terbinafine Hcl | 69 | $422 |
| Methylprednisolone | 59 | $404 |
| Mupirocin | 42 | $370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $301 | $44,77549 claims |
| Smith+NephewSantyl | $440 | $17,56723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 294 foot surgery providers in New York.
Other foot surgery in Brooklyn
- Lawrence SantiBrooklyn$25K
- Evan BrethBrooklyn$17K
- Ilya ShnitserBrooklyn$11K
- Susan SchneidermesserBrooklyn$6K
- Irina BelderBrooklyn$5K
- Leon StepenskyBrooklyn$4K
- Nicholas DangeloBrooklyn$4K
- Svetlana LuvishBrooklyn$4K
- Salvatore GaudinoBrooklyn$4K
- Paul LiswoodBrooklyn$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.